Skip to main content

Advertisement

Springer Nature is making SARS-CoV-2 and COVID-19 research free. View research | View latest news | Sign up for updates

Table 3 Discriminatory antibodies for CD8+ T cellsa

From: Antibody microarray analysis of cell surface antigens on CD4+ and CD8+ T cells from HIV+ individuals correlates with disease stages

Discriminatory Antibody Up(+)/Down(-) P Value
BDL vs. NEG   
CD57 + 0.0272
CD45RO + 0.0307
HLA-DR + 0.0315
CD95 + 0.0538
LTNP vs. NEG   
HLA-DR + 0.0039
CD11c + 0.0072
CD38 + 0.0219
CD27 PH - 0.0310
CD95 + 0.0545
CD57 + 0.0591
CD16 + 0.0631
CD212b1 + 0.0745
CD45RO + 0.0953
VIR vs. NEG   
CD57 + 0.0006
CD45RO + 0.0067
CD38 + 0.0091
CD95 + 0.0091
HLA-DR + 0.0190
CD9 - 0.0268
CD212b1 + 0.0776
BDL vs. LTNP   
CD11c - 0.0049
CD16 - 0.0093
CD56 - 0.0871
VIR vs. LTNP   
CD11c - 0.0017
CD56 - 0.0121
CD16 - 0.0308
CD27PH + 0.0585
CD9 - 0.0862
VIR vs. BDL   
CD38 + 0.0124
  1. aSix paired comparisons of CD markers on CD8+ cells providing significant discrimination between patient groups, with relative changes in CD antigen binding in the former vs. the latter denoted by "+" and "-" to indicate increase and decrease, respectively. Antigens that did not achieve statistical significance (p > 0.05) but have been previously reported in HIV disease context or have been found to be significant in other pair comparisons are also shown in italic.